FILE – Boxes of the drug mifepristone sit on a shelf at the West Alabama Women’s Center in Tuscaloosa, Ala., on March 16, 2022. The Supreme Court is being asked to reverse an appellate ruling that would cut off mail-order access to a drug used in the most common method of abortion in the United States. In an appeal filed Friday, Sept. 8, 2023, Danco Laboratories, the manufacturer of mifepristone, argued that federal judges should not second-guess the Food and Drug Administration’s approval of the drug or the conditions under which it is dispensed. The Supreme Court agreed Dec. 13, 2023 to consider the case.
Leave a Reply